Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Safety of Ovine Enoxaparin Sodium in NSTEACS
NCT06114641Phase 4Completed
- Sponsor
- Bio Farma
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, open-label trial of ovine enoxaparin in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) (2 arms), sponsored by Bio Farma. Primary endpoint: Proportion of death, recurrent or refractory angina, and stroke during hospitalization at 10 days. Started Jun 2023; status: completed.
02
Drugs
ovine enoxaparin
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT06114641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114641.